Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day Transcript

SA Transcripts159.19K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day April 2, 2026 10:00 AM EDT Company Participants Mercedes Carrasco - Senior Director of Investor & Corporate CommunicationsJohn Butler - CEO, President & DirectorSteven Burke - Senior VP and Chief Research & Development Officer Conference Call Participants James A. TumlinV. Michael HolersJonathan Barratt Presentation Operator Good morning, and welcome to the Akebia Therapeutics R&D Day. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Akebia website following the conclusion of the event. I'd now like to turn the call over to Mercedes Carrasco, Senior Director of Investor Relations and Communications at Akebia Therapeutics. Please go ahead, Mercedes. Mercedes CarrascoSenior Director of Investor & Corporate Communications Good morning, and welcome to Akebia's Research and Development Day. During the presentation, we will be making forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those described in these statements. For more information, please refer to the SEC statements available on our website. For your convenience, a replay of today's call will also be available on our website after we conclude. To begin, John Butler, Akebia President and CEO, will present opening remarks and a brief company and pipeline overview.

Akebia Chief Medical Officer, Dr. Steven Burke, will be joined by Dr. James Tumlin to review praliciguat, which is being studied for FSGS. Dr. Burke will then be joined by Dr. Michael Holers and Jonathan Barratt to discuss our complement inhibitor, AKB-097, and he will close with an overview of AKB-9090. Following the formal presentation, we will open for Q&A. With that, I will turn now to John Butler to begin. John ButlerCEO, President & Director